Molecular Imaging in Recurrent Prostate Cancer Presented as a Mixed Small Neuroendocrine Tumor/Acinar Adenocarcinoma

Al‐Ibraheem, Akram; Al-Adhami, Dhuha Ali; Abdlkadir, Ahmed Saad; Al-Hajaj, Nabeela; Ghanem, Rami; Abu-Hijlih, Ramiz; Salah, Samer

doi:10.1007/s13139-023-00800-x

Cited by 4 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the uptake of PET radiotracers targeting PSMA and SSTRs may be reduced and can potentially lead to false negative findings in these cases. This variant of prostate cancer is FDG avid and FDG PET should also be used in these cases [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

A Rare Case of Neuroendocrine Prostate Cancer Detected on 68Ga – DOTANOC Positron Emission Tomography/Computed Tomography (PET/CT)

Kumar,

Prakash,

Kumar Upadhyay

et al. 2024

Cureus

View full text Add to dashboard Cite

Prostate cancer is one of the most common malignancies affecting elderly men worldwide and the fifth leading cause of cancer death in men. Prostate cancer includes many histological variants with the prostatic acinar adenocarcinoma variant accounting for the majority of the diagnosed cases. Other less common histological variants are broadly classified as non-acinar carcinomas. One of the non-acinar carcinoma variants is neuroendocrine prostate cancer (NEPC). NEPC can emerge as a mechanism of treatment resistance in castration-resistant conventional prostate cancer and can also rarely be seen as a primary histological form at the time of initial diagnosis. Like other non-acinar carcinoma variants of prostate cancer, NEPC is also an aggressive variant with associated poor prognosis. Neuroendocrine tumors (NETs) are characterized by the expression of somatostatin receptors (SSTRs). Positron emission tomography/computed tomography (PET/CT) using radiolabeled somatostatin analogs like DOTANOC have been used to detect and stage these NETs. These radiolabeled somatostatin analogs also provide the option of treatment of these tumors and have been used in peptide receptor radionuclide therapy of these tumors. NEPC being a neuroendocrine malignancy also expresses SSTRs and hence can be detected with PET/CT radiotracers like 68Gallium-labeled somatostatin analogs. We here report a case of metastatic treatment-emergent NEPC detected on 68Ga - DOTANOC PET/CT.

show abstract

Section: Discussionmentioning

confidence: 99%

A Rare Case of Neuroendocrine Prostate Cancer Detected on 68Ga – DOTANOC Positron Emission Tomography/Computed Tomography (PET/CT)

Kumar,

Prakash,

Kumar Upadhyay

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…[ 18 F]FDG PET/CT were performed for some patients. This was assessed to determine and ensure no discrepancy with [ 68 Ga]Ga-PSMA PET/CT to exclude tumor heterogeneity or dedifferentiation [ 38 , 39 ].…”

Section: Methodsmentioning

confidence: 99%

From Despair to Hope: First Arabic Experience of 177Lu-PSMA and 161Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer

Al-Ibraheem,

Abdlkadir,

Sweedat

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

The objective of this retrospective study is to assess the effectiveness and safety of two beta-emitting prostate-specific membrane antigen (PSMA) radioligands, [177Lu]Lu and [161Tb]Tb, in heavily treated patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 148 cycles of beta-emitting PSMA radioligand therapy were given to 53 patients at a specialized cancer care center in Amman, Jordan. This treatment was offered following the exhaustion of all prior treatment modalities. Approximately half of the cases (n = 26) demonstrated an initial partial response to PSMA radioligand therapy. Moreover, roughly one-fourth of the patients (n = 13) exhibited a sustained satisfactory biochemical response, which qualified them to receive a total of six PSMA radioligand therapy cycles and maintain continued follow-up for additional treatment cycles. This was reflected by an adequate prostate-specific antigen (PSA) decline and a concomitant partial response evident on [68Ga]Ga-PSMA positron emission tomography/computed tomography imaging. A minority of patients (n= 18; 34%) experienced side effects. Generally, these were low-grade and self-limiting toxicities. This study endorses previous research evidence about PSMA radioligand therapy’s safety and efficacy. It also provides the first clinical insight from patients of Arab ethnicity. This should facilitate and promote further evidence, both regionally and internationally.

show abstract

“…Prostatic adenocarcinoma patients may exhibit atypical malignant, metastatic, and synchronous disease manifestations. [1][2][3][4][5][6][7] Clinical evidence often warrants further investigation. In our patient, there was an insignificant clinical manifestation complicating the issue at hand.…”

Section: Figurementioning

confidence: 99%

“…This was acquired via the concurrent utilization of scintigraphic and molecular imaging evidence. Prostatic adenocarcinoma patients may exhibit atypical malignant, metastatic, and synchronous disease manifestations 1–7 . Clinical evidence often warrants further investigation.…”

mentioning

confidence: 99%

Cerebral and Muscular Metastases From Prostate Adenocarcinoma Initially Depicted by 177Lu-PSMA SPECT/CT

Al-Ibraheem,

Istatieh,

Abdlkadir

et al. 2024

Clin Nucl Med

Self Cite

View full text Add to dashboard Cite

Cerebral and muscular metastases from prostatic adenocarcinoma occur rarely. Patients who develop such metastatic pattern exhibit noticeable symptoms. Herein, we present a 68-year-old man diagnosed with metastatic castrate-resistant prostate cancer. The patient received multiple 177Lu-PSMA cycles. After the last cycle, a posttreatment SPECT/CT suggested disease progression with uncommon metastatic pattern in the right temporal brain lobe and muscles. 68Ga-PSMA PET/CT and brain MRI confirmed these findings. Surprisingly, the patient remained asymptomatic up until the conclusion of the follow-up, which lasted for 3 months. This case emphasizes the importance of posttreatment scintigraphic imaging when other biomarkers are inconclusive.

show abstract

Molecular Imaging in Recurrent Prostate Cancer Presented as a Mixed Small Neuroendocrine Tumor/Acinar Adenocarcinoma

Cited by 4 publications

References 9 publications

A Rare Case of Neuroendocrine Prostate Cancer Detected on 68Ga – DOTANOC Positron Emission Tomography/Computed Tomography (PET/CT)

A Rare Case of Neuroendocrine Prostate Cancer Detected on 68Ga – DOTANOC Positron Emission Tomography/Computed Tomography (PET/CT)

From Despair to Hope: First Arabic Experience of 177Lu-PSMA and 161Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer

Cerebral and Muscular Metastases From Prostate Adenocarcinoma Initially Depicted by 177Lu-PSMA SPECT/CT

Contact Info

Product

Resources

About